AstraZeneca and BenevolentAI announced that they began a long-term collaboration to use artificial intelligence and machine learning for the discovery and development of new treatments for chronic kidney disease and idiopathic pulmonary fibrosis. Mene Pangalos, EVP and President BioPharmaceuticals R&D, said: “The vast amount of data available to research scientists is growing exponentially each year. By combining AstraZeneca’s disease area expertise and large, diverse datasets with BenevolentAI’s leading AI and machine learning capabilities, we can unlock the potential of this wealth of data to improve our understanding of complex disease biology and identify new targets that could treat debilitating diseases.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.